Phase I Escalation and Expansion Study of Bemarituzumab (FPA144) in Patients With Advanced Solid Tumors and FGFR2b-Selected Gastroesophageal Adenocarcinoma

PURPOSE: To evaluate the safety, pharmacokinetics, and preliminary activity of bemarituzumab in patients with FGFR2b-overexpressing gastric and gastroesophageal junction adenocarcinoma (GEA). PATIENTS AND METHODS: FPA144-001 was a phase I, open-label, multicenter trial consisting of the following 3...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:J Clin Oncol
Asıl Yazarlar: Catenacci, Daniel V.T., Rasco, Drew, Lee, Jeeyun, Rha, Sun Young, Lee, Keun-Wook, Bang, Yung Jue, Bendell, Johanna, Enzinger, Peter, Marina, Neyssa, Xiang, Hong, Deng, Wei, Powers, Janine, Wainberg, Zev A.
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: American Society of Clinical Oncology 2020
Konular:
ORIGINAL REPORTS
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC7367551/
https://ncbi.nlm.nih.gov/pubmed/32167861
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.19.01834
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller